Genetics in Medicine Open (Jan 2024)

Combining rare and common genetic variants improves population risk stratification for breast cancer

  • Alexandre Bolze,
  • Daniel Kiser,
  • Kelly M. Schiabor Barrett,
  • Gai Elhanan,
  • Jamie M. Schnell Blitstein,
  • Iva Neveux,
  • Shaun Dabe,
  • Harry Reed,
  • Alexa Anderson,
  • William J. Metcalf,
  • Ekaterina Orlova,
  • Ildiko Thibodeau,
  • Natalie Telis,
  • Ruomu Jiang,
  • Nicole L. Washington,
  • Matthew J. Ferber,
  • Catherine Hajek,
  • Elizabeth T. Cirulli,
  • Joseph J. Grzymski

Journal volume & issue
Vol. 2
p. 101826

Abstract

Read online

Purpose: This study aimed to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer in the general population. Methods: We retrospectively studied 25,591 women with available electronic health records and genetic data, participants in the Healthy Nevada Project. Results: Family history of breast cancer was ascertained on or after the record of breast cancer for 78% of women with both, indicating that this risk assessment method is not being properly utilized for early screening. Genetics offered an alternative method for risk assessment. 11.4% of women were identified as high risk based on possessing a predicted loss-of-function (pLOF) variant in BRCA1, BRCA2, or PALB2 (hazard ratio = 10.4, 95% confidence interval: 8.1-13.5) or a pLOF variant in ATM or CHEK2 (hazard ratio = 3.4, CI: 2.4-4.8) or being in the top 10% of the polygenic risk score (PRS) distribution (hazard ratio = 2.4, CI: 2.0-2.8). Moreover, women with a pLOF in ATM or CHEK2 and ranking in the top 50% of the PRS displayed a high risk (39.2% probability of breast cancer at age 70), whereas their counterparts in the bottom 50% of the PRS were not at high risk (14.4% probability at age 70). Conclusion: Our findings suggest that a combined monogenic and polygenic approach allowed a better identification of participants with high risk while minimizing false positives.

Keywords